Skip to Main Content
Project on Government Oversight
 

 

 

 

POGO's Statement on the FDA's Decision to Keep Avandia on the Market

September 23, 2010 

 

In response to today's decision by the FDA to keep Avandia on the market.

"With all the evidence of misconduct by GlaxoSmithKline provided by Congress and the plethora of studies conducted by outside experts showing harm, you have to wonder what type of evidence the FDA needs to withdraw a drug," said Paul Thacker, an investigator for the Project On Government Oversight and former lead investigator on Avandia for Senator Chuck Grassley, Ranking Member of the Senate Finance Committee.  "Apparently, all drugs are innocent until overwhelming, incontrovertible proof finds them guilty of harming Americans."

Thacker went on to state: "The FDA and GlaxoSmithKline have not provided evidence that patients cannot do fine with other available drugs.  And the fact that the agency made this decision despite advice from the FDA's Office of Surveillance and Epidemiology (OSE) to withdraw Avandia could be perceived as ignoring Congress, which has pushed the agency to give more weight to the advice from scientific experts."

GlaxoSmithKline (GSK), which once ranked among the 100 largest federal contractors and is currently 102, is in POGO's Federal Contractor Misconduct Database. GSK currently has 22 instances of misconduct.


Founded in 1981, the Project On Government Oversight (POGO) is a nonpartisan independent watchdog that champions good government reforms. POGO's investigations into corruption, misconduct, and conflicts of interest achieve a more effective, accountable, open, and ethical federal government.

# # #